Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis
Published: May 12, 2011
The trial was designed to evaluate the safety, tolerability and pharmacokinetics of AB103. It was a double blind, placebo controlled study that included 25 healthy volunteers receiving escalating single doses of AB103. The study was conducted at the University of Maryland in Baltimore, US.